Repligen closes BioLife Solutions buy for $11.25 cash plus 0.1442 RGEN shares per share

REPLIGEN CORP

BioLife stockholders received $11.25 in cash plus 0.1442 shares of Repligen common stock per share, with cash in lieu of fractional shares.
Mergers closed October 6, 2026 under the July 21, 2026 agreement; BioLife ceased to exist as a separate legal entity and became a Repligen subsidiary.
BioLife Common Stock is being delisted from Nasdaq via Form 25, with a Form 15 planned to suspend reporting obligations under Sections 13 and 15(d).
BioLife's CryoStor-led biopreservation media serves 18 commercially approved therapies and the majority of U.S. commercially sponsored cell-based therapy trials.
Repligen says the deal adds a high-margin consumables franchise with recurring revenue and Asia Pacific reach; 2026 outlook impact to be detailed on the Q3 2026 earnings call.

This headline and bullets were generated automatically by deepseek-v4.1-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.